Organon & Co. (NYSE:OGN) Shares Sold by Cwm LLC

Cwm LLC decreased its holdings in Organon & Co. (NYSE:OGN) by 14.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 27,786 shares of the company’s stock after selling 4,684 shares during the period. Cwm LLC’s holdings in Organon & Co. were worth $532,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also modified their holdings of the company. Atomi Financial Group Inc. grew its stake in Organon & Co. by 26.5% during the 3rd quarter. Atomi Financial Group Inc. now owns 42,034 shares of the company’s stock worth $804,000 after purchasing an additional 8,811 shares in the last quarter. Foresight Capital Management Advisors Inc. acquired a new position in shares of Organon & Co. during the third quarter worth about $1,013,000. Diversified Trust Co purchased a new stake in shares of Organon & Co. during the third quarter worth approximately $416,000. GAMMA Investing LLC raised its holdings in Organon & Co. by 57.6% in the third quarter. GAMMA Investing LLC now owns 6,362 shares of the company’s stock valued at $122,000 after acquiring an additional 2,326 shares in the last quarter. Finally, Handelsbanken Fonder AB lifted its stake in Organon & Co. by 6.6% in the third quarter. Handelsbanken Fonder AB now owns 68,250 shares of the company’s stock worth $1,306,000 after acquiring an additional 4,250 shares during the last quarter. Hedge funds and other institutional investors own 77.43% of the company’s stock.

Wall Street Analyst Weigh In

OGN has been the topic of a number of recent analyst reports. Evercore ISI raised shares of Organon & Co. to a “strong-buy” rating in a research report on Wednesday, September 18th. JPMorgan Chase & Co. lowered Organon & Co. from a “neutral” rating to an “underweight” rating and increased their target price for the company from $18.00 to $20.00 in a report on Friday, September 6th.

Organon & Co. Stock Performance

Shares of OGN opened at $17.61 on Friday. The company has a quick ratio of 1.17, a current ratio of 1.64 and a debt-to-equity ratio of 60.05. Organon & Co. has a 52-week low of $10.84 and a 52-week high of $23.10. The stock has a 50 day moving average price of $19.98 and a 200 day moving average price of $20.14. The company has a market capitalization of $4.53 billion, a price-to-earnings ratio of 4.53, a price-to-earnings-growth ratio of 0.79 and a beta of 0.84.

Organon & Co. (NYSE:OGN) last posted its earnings results on Tuesday, August 6th. The company reported $1.12 EPS for the quarter, beating analysts’ consensus estimates of $1.08 by $0.04. Organon & Co. had a net margin of 15.76% and a negative return on equity of 840.29%. The firm had revenue of $1.61 billion for the quarter, compared to the consensus estimate of $1.61 billion. During the same period last year, the firm posted $1.31 EPS. The company’s revenue was down .1% on a year-over-year basis. Research analysts predict that Organon & Co. will post 4.15 EPS for the current fiscal year.

Organon & Co. Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, September 12th. Stockholders of record on Friday, August 16th were given a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a dividend yield of 6.36%. The ex-dividend date was Friday, August 16th. Organon & Co.’s dividend payout ratio (DPR) is currently 28.79%.

Organon & Co. Company Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.